title: Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients.
abstract: Paragangliomas are rare tumors that arise from extraadrenal chromaffin cells. We examined the clinical characteristics, location, treatment, and outcome of 236 patients (141 females, 60%) with 297 benign paragangliomas evaluated at the Mayo Clinic during 1978-1998. The mean age (+/-SD) at diagnosis was 47 +/- 16 yr. Of the 297 paragangliomas, 205 were in the head and neck region, and 92 were below the neck. Paragangliomas were discovered and diagnosed incidentally on imaging studies in 9% of patients. Biochemical screening was performed in 128 patients; 40 patients (17% of the total and 31% of those screened) had hyperfunctional tumors. Of the 40 patients with tumoral catecholamine excess, 38 had documented hypertension. In patients identified with catecholamine-secreting paragangliomas, the sensitivities achieved by measurements in the 24-h urine collection were 74% for total metanephrines, 84% for norepinephrine, 18% for dopamine, and 14% for epinephrine. Multiple imaging modalities were used for tumor localization. The false negative rates were 0% for magnetic resonance imaging, 5.8% for computed tomography, 3.4% for angiography, 10.7% for ultrasonography, and 39% for radioactive iodine-labeled metaiodobenzylguanidine scintigraphy. Of 192 patients (81.4%) with follow-up data (mean, 43.9 months; range, 0.5-240), operative cure was achieved in 133 (69%). Of the 59 patients without cure, 23 had persistent disease, 5 had recurrent disease, 16 had multiple persistent synchronous tumors, and 15 subsequently developed metachronous tumors. In conclusion, most paragangliomas are nonhypersecretory and located in the head and neck region. Magnetic resonance imaging was associated with the lowest false negative rate, and metaiodobenzylguanidine was the least sensitive imaging study. A significant proportion of patients (31%) has persistent or recurrent disease, and long-term follow-up is important.
authors.affiliation: Division of Endocrinology, Metabolism, Nutrition, and Internal Medicine, Mayo Clinic, and Mayo Foundation, Rochester, Minnesota 55905, USA.
authors.forename: D
authors.initials: D
authors.lastname: Erickson
authors.forename: Y C
authors.initials: YC
authors.lastname: Kudva
authors.forename: M J
authors.initials: MJ
authors.lastname: Ebersold
authors.forename: G B
authors.initials: GB
authors.lastname: Thompson
authors.forename: C S
authors.initials: CS
authors.lastname: Grant
authors.forename: J A
authors.initials: JA
authors.lastname: van Heerden
authors.forename: W F
authors.initials: WF
authors.lastname: Young
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002395:Catecholamines / Q000652:urine; D002851:Chromatography, High Pressure Liquid; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007462:Iodobenzenes / Q000652:urine; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D010235:Paraganglioma / Q000175:diagnosis* / Q000378:metabolism / Q000628:therapy*; D014057:Tomography, X-Ray Computed
chemical_list: D002395:Catecholamines; D007462:Iodobenzenes; C025423:4-iodobenzylguanidine